Trial Profile
A Randomized Phase IIa Study of TAS-205 in Patients With Duchenne Muscular Dystrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Apr 2020
Price :
$35
*
At a glance
- Drugs Pizuglanstat (Primary)
- Indications Duchenne muscular dystrophy
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 05 Feb 2018 Status changed from active, no longer recruiting to completed.
- 26 Dec 2016 Status changed from recruiting to active, no longer recruiting.
- 10 May 2016 Status changed from not yet recruiting to recruiting.